Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC boosted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 21.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 89,132 shares of the company’s stock after buying an additional 15,831 shares during the quarter. Fisher Asset Management LLC owned 0.09% of Day One Biopharmaceuticals worth $1,129,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in Day One Biopharmaceuticals during the fourth quarter worth about $31,000. Mirae Asset Global Investments Co. Ltd. grew its position in Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after buying an additional 1,002 shares during the period. Quest Partners LLC grew its position in Day One Biopharmaceuticals by 9,238.6% during the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after buying an additional 7,668 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Day One Biopharmaceuticals during the third quarter worth about $174,000. Finally, XTX Topco Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the third quarter valued at approximately $178,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $9.70 on Thursday. Day One Biopharmaceuticals, Inc. has a 1 year low of $8.02 and a 1 year high of $18.07. The firm’s 50 day moving average price is $11.93 and its 200 day moving average price is $13.27. The firm has a market cap of $983.14 million, a P/E ratio of -9.42 and a beta of -1.46.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million for the quarter, compared to analysts’ expectations of $27.11 million. As a group, equities analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright lowered their price target on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. JPMorgan Chase & Co. lowered their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, Bank of America lowered their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $34.57.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 4,370 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the transaction, the chief financial officer now owns 252,638 shares of the company’s stock, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total transaction of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. This represents a 2.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,064 shares of company stock valued at $651,225 over the last quarter. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.